PubRank

Tyler Jacks

Author PubWeight™ 460.54‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 MicroRNA expression profiles classify human cancers. Nature 2005 69.12
2 Chromatin signature reveals over a thousand highly conserved large non-coding RNAs in mammals. Nature 2009 35.48
3 Impaired microRNA processing enhances cellular transformation and tumorigenesis. Nat Genet 2007 15.46
4 Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell 2003 15.43
5 Identification of bronchioalveolar stem cells in normal lung and lung cancer. Cell 2005 15.06
6 Restoration of p53 function leads to tumour regression in vivo. Nature 2007 12.62
7 Targeted deletion reveals essential and overlapping functions of the miR-17 through 92 family of miRNA clusters. Cell 2008 12.29
8 A large intergenic noncoding RNA induced by p53 mediates global gene repression in the p53 response. Cell 2010 12.27
9 Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature 2009 11.46
10 An oncogenic KRAS2 expression signature identified by cross-species gene-expression analysis. Nat Genet 2004 10.92
11 Cre-lox-regulated conditional RNA interference from transgenes. Proc Natl Acad Sci U S A 2004 9.33
12 Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome. Cell 2004 8.48
13 Endogenous oncogenic K-ras(G12D) stimulates proliferation and widespread neoplastic and developmental defects. Cancer Cell 2004 8.16
14 MicroRNAs and cancer: short RNAs go a long way. Cell 2009 7.25
15 Suppression of non-small cell lung tumor development by the let-7 microRNA family. Proc Natl Acad Sci U S A 2008 6.89
16 Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells. Cell 2009 6.55
17 Acute mutation of retinoblastoma gene function is sufficient for cell cycle re-entry. Nature 2003 6.01
18 The differential effects of mutant p53 alleles on advanced murine lung cancer. Cancer Res 2005 5.93
19 Dicer1 functions as a haploinsufficient tumor suppressor. Genes Dev 2009 5.21
20 Differential effects of oncogenic K-Ras and N-Ras on proliferation, differentiation and tumor progression in the colon. Nat Genet 2008 5.07
21 Role of K-ras and Pten in the development of mouse models of endometriosis and endometrioid ovarian cancer. Nat Med 2004 4.98
22 Requirement for NF-kappaB signalling in a mouse model of lung adenocarcinoma. Nature 2009 4.93
23 AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer. Cancer Cell 2009 4.71
24 p63 and p73 are required for p53-dependent apoptosis in response to DNA damage. Nature 2002 4.56
25 Conditional mouse lung cancer models using adenoviral or lentiviral delivery of Cre recombinase. Nat Protoc 2009 4.50
26 Tumor predisposition in mice mutant for p63 and p73: evidence for broader tumor suppressor functions for the p53 family. Cancer Cell 2005 4.14
27 A spatially and temporally restricted mouse model of soft tissue sarcoma. Nat Med 2007 3.96
28 Expression of tumour-specific antigens underlies cancer immunoediting. Nature 2012 3.89
29 Growth-inhibitory and tumor- suppressive functions of p53 depend on its repression of CD44 expression. Cell 2008 3.75
30 Conditional expression of oncogenic K-ras from its endogenous promoter induces a myeloproliferative disease. J Clin Invest 2004 3.47
31 Classification of proliferative pulmonary lesions of the mouse: recommendations of the mouse models of human cancers consortium. Cancer Res 2004 3.43
32 Context-dependent transformation of adult pancreatic cells by oncogenic K-Ras. Cancer Cell 2009 3.37
33 Treating metastatic cancer with nanotechnology. Nat Rev Cancer 2011 3.30
34 Suppression of lung adenocarcinoma progression by Nkx2-1. Nature 2011 3.27
35 Cancer modeling in the modern era: progress and challenges. Cell 2002 3.12
36 Mechanism for the learning deficits in a mouse model of neurofibromatosis type 1. Nature 2002 3.05
37 Stage-specific sensitivity to p53 restoration during lung cancer progression. Nature 2010 3.03
38 Autophagy suppresses progression of K-ras-induced lung tumors to oncocytomas and maintains lipid homeostasis. Genes Dev 2013 2.90
39 Single-molecule transcript counting of stem-cell markers in the mouse intestine. Nat Cell Biol 2011 2.72
40 PKM2 isoform-specific deletion reveals a differential requirement for pyruvate kinase in tumor cells. Cell 2013 2.38
41 Nuclear factor I/B is an oncogene in small cell lung cancer. Genes Dev 2011 2.29
42 Targeted point mutations of p53 lead to dominant-negative inhibition of wild-type p53 function. Proc Natl Acad Sci U S A 2002 2.24
43 Merlin, the product of the Nf2 tumor suppressor gene, is an inhibitor of the p21-activated kinase, Pak1. Mol Cell 2003 2.23
44 Cell type-specific effects of Rb deletion in the murine retina. Genes Dev 2004 2.18
45 p53 controls radiation-induced gastrointestinal syndrome in mice independent of apoptosis. Science 2009 2.11
46 Nkx2-1 represses a latent gastric differentiation program in lung adenocarcinoma. Mol Cell 2013 2.05
47 Proliferation and tumorigenesis of a murine sarcoma cell line in the absence of DICER1. Cancer Cell 2012 2.04
48 Suppression of Rev3, the catalytic subunit of Pol{zeta}, sensitizes drug-resistant lung tumors to chemotherapy. Proc Natl Acad Sci U S A 2010 1.95
49 Chronic cisplatin treatment promotes enhanced damage repair and tumor progression in a mouse model of lung cancer. Genes Dev 2010 1.95
50 Use of gene expression profiling to direct in vivo molecular imaging of lung cancer. Proc Natl Acad Sci U S A 2005 1.91
51 Endogenous T cell responses to antigens expressed in lung adenocarcinomas delay malignant tumor progression. Cancer Cell 2011 1.89
52 HIF-2alpha deletion promotes Kras-driven lung tumor development. Proc Natl Acad Sci U S A 2010 1.86
53 The related retinoblastoma (pRb) and p130 proteins cooperate to regulate homeostasis in the intestinal epithelium. J Biol Chem 2005 1.85
54 Merlin phosphorylation by p21-activated kinase 2 and effects of phosphorylation on merlin localization. J Biol Chem 2002 1.82
55 Sprouty-2 regulates oncogenic K-ras in lung development and tumorigenesis. Genes Dev 2007 1.81
56 ROS fusion tyrosine kinase activates a SH2 domain-containing phosphatase-2/phosphatidylinositol 3-kinase/mammalian target of rapamycin signaling axis to form glioblastoma in mice. Cancer Res 2006 1.80
57 Requirement for Rac1 in a K-ras induced lung cancer in the mouse. Cancer Res 2007 1.80
58 A functional switch from lung cancer resistance to susceptibility at the Pas1 locus in Kras2LA2 mice. Nat Genet 2006 1.79
59 Chimeric mouse tumor models reveal differences in pathway activation between ERBB family- and KRAS-dependent lung adenocarcinomas. Nat Biotechnol 2009 1.76
60 Characterizing deformability and surface friction of cancer cells. Proc Natl Acad Sci U S A 2013 1.72
61 Progesterone receptor expression in neurofibromas. Cancer Res 2003 1.72
62 Mist1-KrasG12D knock-in mice develop mixed differentiation metastatic exocrine pancreatic carcinoma and hepatocellular carcinoma. Cancer Res 2006 1.69
63 Targeted deletion reveals an essential function for the telomere length regulator Trf1. Mol Cell Biol 2003 1.69
64 The Rb tumor suppressor is required for stress erythropoiesis. EMBO J 2004 1.68
65 Selective killing of K-ras mutant cancer cells by small molecule inducers of oxidative stress. Proc Natl Acad Sci U S A 2011 1.68
66 The comparative pathology of genetically engineered mouse models for neuroendocrine carcinomas of the lung. J Thorac Oncol 2015 1.68
67 Optimality in the development of intestinal crypts. Cell 2012 1.67
68 A reversible gene-targeting strategy identifies synthetic lethal interactions between MK2 and p53 in the DNA damage response in vivo. Cell Rep 2013 1.67
69 Dynamic regulation of the Ras pathway via proteolysis of the NF1 tumor suppressor. Genes Dev 2003 1.64
70 An induced Ets repressor complex regulates growth arrest during terminal macrophage differentiation. Cell 2002 1.63
71 Defective apoptosis and B-cell lymphomas in mice with p53 point mutation at Ser 23. EMBO J 2004 1.63
72 Activation of the p53-dependent G1 checkpoint response in mouse embryo fibroblasts depends on the specific DNA damage inducer. Oncogene 2004 1.61
73 Hematopoiesis and leukemogenesis in mice expressing oncogenic NrasG12D from the endogenous locus. Blood 2010 1.60
74 Susceptibility to astrocytoma in mice mutant for Nf1 and Trp53 is linked to chromosome 11 and subject to epigenetic effects. Proc Natl Acad Sci U S A 2004 1.55
75 Imaging primary lung cancers in mice to study radiation biology. Int J Radiat Oncol Biol Phys 2010 1.48
76 Response and resistance to NF-κB inhibitors in mouse models of lung adenocarcinoma. Cancer Discov 2011 1.46
77 Murine bilateral retinoblastoma exhibiting rapid-onset, metastatic progression and N-myc gene amplification. EMBO J 2007 1.46
78 Increased sensitivity to UV radiation in mice with a p53 point mutation at Ser389. Mol Cell Biol 2004 1.44
79 Recapitulation of the effects of the human papillomavirus type 16 E7 oncogene on mouse epithelium by somatic Rb deletion and detection of pRb-independent effects of E7 in vivo. Mol Cell Biol 2003 1.43
80 p63 and p73 transcriptionally regulate genes involved in DNA repair. PLoS Genet 2009 1.41
81 Cross species genomic analysis identifies a mouse model as undifferentiated pleomorphic sarcoma/malignant fibrous histiocytoma. PLoS One 2009 1.40
82 Comparison of gene expression and DNA copy number changes in a murine model of lung cancer. Genes Chromosomes Cancer 2006 1.36
83 RB signaling prevents replication-dependent DNA double-strand breaks following genotoxic insult. Nucleic Acids Res 2004 1.33
84 A physical sciences network characterization of non-tumorigenic and metastatic cells. Sci Rep 2013 1.33
85 Mammalian RNAi: a practical guide. Biotechniques 2005 1.32
86 ARF is not required for apoptosis in Rb mutant mouse embryos. Curr Biol 2002 1.30
87 Tissue-specific p19Arf regulation dictates the response to oncogenic K-ras. Proc Natl Acad Sci U S A 2010 1.28
88 Caspase-2-mediated cleavage of Mdm2 creates a p53-induced positive feedback loop. Mol Cell 2011 1.27
89 Mice expressing a mammary gland-specific R270H mutation in the p53 tumor suppressor gene mimic human breast cancer development. Cancer Res 2005 1.26
90 Regulated expression of a tumor-associated antigen reveals multiple levels of T-cell tolerance in a mouse model of lung cancer. Cancer Res 2008 1.25
91 Cellular transformation by a FERM domain mutant of the Nf2 tumor suppressor gene. Oncogene 2002 1.23
92 Cyclooxygenase-1 is overexpressed in multiple genetically engineered mouse models of epithelial ovarian cancer. Cancer Res 2006 1.22
93 Uncoupling cancer mutations reveals critical timing of p53 loss in sarcomagenesis. Cancer Res 2011 1.21
94 The Nf2 tumor suppressor regulates cell-cell adhesion during tissue fusion. Proc Natl Acad Sci U S A 2007 1.17
95 Impaired SHP2-mediated extracellular signal-regulated kinase activation contributes to gefitinib sensitivity of lung cancer cells with epidermal growth factor receptor-activating mutations. Cancer Res 2010 1.16
96 ARF mutation accelerates pituitary tumor development in Rb+/- mice. Proc Natl Acad Sci U S A 2002 1.15
97 Technologically advanced cancer modeling in mice. Curr Opin Genet Dev 2002 1.14
98 p53 constrains progression to anaplastic thyroid carcinoma in a Braf-mutant mouse model of papillary thyroid cancer. Proc Natl Acad Sci U S A 2014 1.14
99 Dominant role of oncogene dosage and absence of tumor suppressor activity in Nras-driven hematopoietic transformation. Cancer Discov 2013 1.13
100 Requirement of c-Jun NH(2)-terminal kinase for Ras-initiated tumor formation. Mol Cell Biol 2011 1.12
101 Multiple response elements and differential p53 binding control Perp expression during apoptosis. Mol Cancer Res 2003 1.11
102 Perp is a mediator of p53-dependent apoptosis in diverse cell types. Curr Biol 2003 1.11
103 Efficacy of sunitinib and radiotherapy in genetically engineered mouse model of soft-tissue sarcoma. Int J Radiat Oncol Biol Phys 2009 1.09
104 Coordinate loss of a microRNA and protein-coding gene cooperate in the pathogenesis of 5q- syndrome. Blood 2011 1.08
105 SnapShot: Lung cancer models. Cell 2012 1.05
106 Discrete signaling pathways participate in RB-dependent responses to chemotherapeutic agents. Oncogene 2004 1.05
107 Rb and N-ras function together to control differentiation in the mouse. Mol Cell Biol 2003 1.03
108 Dominant-negative but not gain-of-function effects of a p53.R270H mutation in mouse epithelium tissue after DNA damage. Cancer Res 2007 1.01
109 A big step in the study of small cell lung cancer. Cancer Cell 2003 1.00
110 Differential Tks5 isoform expression contributes to metastatic invasion of lung adenocarcinoma. Genes Dev 2013 1.00
111 Integrated cistromic and expression analysis of amplified NKX2-1 in lung adenocarcinoma identifies LMO3 as a functional transcriptional target. Genes Dev 2013 1.00
112 Progressive genomic instability in the FVB/Kras(LA2) mouse model of lung cancer. Mol Cancer Res 2011 0.96
113 A mouse plasma peptide atlas as a resource for disease proteomics. Genome Biol 2008 0.96
114 Future of early detection of lung cancer: the role of mouse models. Clin Cancer Res 2005 0.95
115 Inhibition of oncogenic K-ras signaling by aerosolized gene delivery in a mouse model of human lung cancer. Clin Cancer Res 2002 0.93
116 Tumor suppression by a severely truncated species of retinoblastoma protein. Mol Cell Biol 2002 0.91
117 Pten-null tumors cohabiting the same lung display differential AKT activation and sensitivity to dietary restriction. Cancer Discov 2013 0.90
118 Mutation at p53 serine 389 does not rescue the embryonic lethality in mdm2 or mdm4 null mice. Oncogene 2004 0.89
119 Genetically engineered mouse models of cancer reveal new insights about the antitumor immune response. Curr Opin Immunol 2013 0.89
120 Lack of p53 Ser389 phosphorylation predisposes mice to develop 2-acetylaminofluorene-induced bladder tumors but not ionizing radiation-induced lymphomas. Cancer Res 2005 0.89
121 Thinking beyond the tumor cell: Nf1 haploinsufficiency in the tumor environment. Cancer Cell 2002 0.88
122 Modulation of tumor induction and progression of oncogenic K-ras-positive tumors in the presence of TGF- b1 haploinsufficiency. Carcinogenesis 2007 0.87
123 Layilin, a cell surface hyaluronan receptor, interacts with merlin and radixin. Exp Cell Res 2005 0.83
124 Defective proliferative responses in B lymphocytes and thymocytes that lack neurofibromin. Mol Immunol 2002 0.83
125 Protein 4.1B expression is induced in mammary epithelial cells during pregnancy and regulates their proliferation. Oncogene 2005 0.83
126 Characterization of Pheochromocytomas in a Mouse Strain with a Targeted Disruptive Mutation of the Neurofibromatosis Gene Nf1. Endocr Pathol 1995 0.83
127 NF-kappaB fans the flames of lung carcinogenesis. Cancer Prev Res (Phila) 2010 0.82
128 Marked regression of metastatic pilocytic astrocytoma during treatment with imatinib mesylate (STI-571, Gleevec): a case report and laboratory investigation. J Pediatr Hematol Oncol 2003 0.82
129 Genetic and cellular mechanisms of oncogenesis. Curr Opin Genet Dev 2008 0.81
130 The next generation of orthotopic thyroid cancer models: immunocompetent orthotopic mouse models of BRAF V600E-positive papillary and anaplastic thyroid carcinoma. Thyroid 2014 0.78
131 Targeting cancer: an interview with Tyler Jacks. Interview by Kathy Weston. Dis Model Mech 2010 0.76
132 Immunology. Guilty by association. Science 2013 0.75
133 Corrigendum: In vivo genome editing and organoid transplantation models of colorectal cancer and metastasis. Nat Biotechnol 2017 0.75
134 Neurofibromatosis type 1. Methods Mol Biol 2003 0.75
135 Corrigendum: Dicer loss and recovery induce an oncogenic switch driven by transcriptional activation of the oncofetal Imp1-3 family. Genes Dev 2017 0.75